Announcement of Licensing Agreement for Acute Myeloid Leukemia Treatment Ortacitinib to Orient Europharma Co., Ltd. (Taiwan)

Contract Overview

Kissei Pharmaceutical Co., Ltd. has entered into a sublicense agreement granting development and marketing rights of the acute myeloid leukemia treatment Ortacitinib to Orient Europharma Co., Ltd. in Taiwan. Under this agreement, OEP will conduct development and commercialization in Taiwan, while Kissei Pharmaceutical will receive upfront and milestone payments and supply formulations. OEP is also the licensee for Kissei’s diabetes treatment GlufastⓇ in Taiwan, establishing a long-term collaborative relationship.

Outlook and Earnings Guidance

The consolidated earnings forecast for the fiscal year ending March 2027, reflecting the impact of this agreement, will be disclosed at the financial results announcement for the fiscal year ending March 2026 scheduled on May 11, 2026. Kissei Pharmaceutical will continue to collaborate with its partners to advance development in licensed territories and accelerate early patient access to Ortacitinib.